NordicRWE, an emerging company specializing in real-world evidence (RWE) generation that NLS has recently interviewed, has officially become a member of AstraZeneca’s BioVentureHub.

This marks an important milestone in the company’s journey, it states.

“We are excited to join the BioVentureHub community, renowned for its collaborative spirit and innovation. This unique opportunity enables us to seek valuable guidance, explore potential collaborations with AstraZeneca R&D, and shape our research programs in Real-World Evidence. Our goal is not only to benefit from the incredible resources within the BioVentureHub, but also to actively contribute to its culture of ‘dare to share.’ As the first fully dedicated RWE company and the first Norwegian company to join, we are eager to share our expertise and guide the community,” says Christian Jonasson, Research Director, NordicRWE.

Bridging the gap between clinical research and practice

“Real World Evidence (RWE) is pivotal in advancing evidence-based medicine, bridging the gap between clinical research and practice. Partnering with stakeholders across the healthcare community to drive evidence-based medicine is crucial in our pursuit of better healthcare outcomes. NordicRWE’s dedication to data-driven drug development aligns with our vision. We are looking forward to learn more, collaborate, maximize RWD assets, drive innovation, and to address unmet medical needs,” says Nina Mian, Executive Director, Head of Data Science & Advanced Analytics, AstraZeneca.

The first Norwegian company in BioVentureHub

NordicRWE is the first Norwegian company joining the BioVentureHub, and a result of the Memorandum of Understanding signed in December 2023, with the aim to stimulate innovation and further developing the Nordic life science ecosystem. The Memorandum of Understanding was signed between Oslo Cancer Cluster, Oslo Science City and AstraZeneca BioVentureHub.